These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23934763)

  • 21. Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome.
    Xu XH; Huang LS; Yang J; Yu T; Tong JF; Yuan XG; Zhao XY
    Leuk Lymphoma; 2013 Jan; 54(1):195-7. PubMed ID: 22574970
    [No Abstract]   [Full Text] [Related]  

  • 22. Front-line TKI therapy for chronic-phase CML: the luxury of choice.
    Shah NP
    Oncology (Williston Park); 2012 Oct; 26(10):908, 910, 912. PubMed ID: 23175996
    [No Abstract]   [Full Text] [Related]  

  • 23. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.
    Chen CI; Koschmieder S; Kerstiens L; Schemionek M; Altvater B; Pscherer S; Gerss J; Maecker HT; Berdel WE; Juergens H; Lee PP; Rossig C
    Leukemia; 2012 Mar; 26(3):465-74. PubMed ID: 21904381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Which TKI should be recommended as initial treatment for CML in chronic phase?
    Schiffer CA
    Oncology (Williston Park); 2012 Oct; 26(10):912, 914. PubMed ID: 23175997
    [No Abstract]   [Full Text] [Related]  

  • 25. Perspective: combined forces.
    Sawyers CL
    Nature; 2013 Jun; 498(7455):S7. PubMed ID: 23803949
    [No Abstract]   [Full Text] [Related]  

  • 26. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
    Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
    Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elderly CML patients' treatment: considering not only physician's judgment but also co-morbidity indexes.
    Sánchez-Guijo F
    Leuk Res; 2014 Oct; 38(10):1156-7. PubMed ID: 25113280
    [No Abstract]   [Full Text] [Related]  

  • 28. Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML.
    Gorkin L; Kantarjian H
    Nat Rev Clin Oncol; 2016 May; 13(5):270-2. PubMed ID: 27098218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone metabolism during long-term treatment with imatinib.
    O'Sullivan S; Horne A; Wattie D; Porteous F; Gamble G; Browett P; Grey A
    Leuk Lymphoma; 2013 Aug; 54(8):1783-5. PubMed ID: 23278638
    [No Abstract]   [Full Text] [Related]  

  • 30. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.
    Irving JA; O'Brien S; Lennard AL; Minto L; Lin F; Hall AG
    Clin Chem; 2004 Jul; 50(7):1233-7. PubMed ID: 15229152
    [No Abstract]   [Full Text] [Related]  

  • 32. Beyond Gleevec--the next generation in CML.
    Fricker J
    Eur J Cancer; 2006 Feb; 42(3):275. PubMed ID: 16514710
    [No Abstract]   [Full Text] [Related]  

  • 33. Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.
    La Rosée P; Hochhaus A
    Curr Hematol Malig Rep; 2008 Apr; 3(2):72-9. PubMed ID: 20425450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of chronic myeloid leukemia with imatinib mesylate.
    Ohno R
    Int J Clin Oncol; 2006 Jun; 11(3):176-83. PubMed ID: 16850123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
    Sawyers CL
    Cancer Cell; 2002 Feb; 1(1):13-5. PubMed ID: 12086882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 38. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
    Sherbenou DW; Hantschel O; Kaupe I; Willis S; Bumm T; Turaga LP; Lange T; Dao KH; Press RD; Druker BJ; Superti-Furga G; Deininger MW
    Blood; 2010 Oct; 116(17):3278-85. PubMed ID: 20519627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dasatinib is effective in imatinib-resistant CML.
    Cannell E
    Lancet Oncol; 2007 Apr; 8(4):286. PubMed ID: 17431950
    [No Abstract]   [Full Text] [Related]  

  • 40. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
    O'Hare T; Eide CA; Deininger MW
    Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.